Evidence map›Paper›PMID 41579215›Full record

ReviewCancer chemotherapy and pharmacology2026

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy.

Xuan Ji, Yalong Yang, Cong Ma, Wenqin Huang, Senyang Guo, Lingzi Wang, Hongmei Zheng, Xinhong Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuan JiBreast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, No.116 Zhuo Daoquan South Road, Wuhan, 430079, Hubei, China.
Yalong YangBreast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, No.116 Zhuo Daoquan South Road, Wuhan, 430079, Hubei, China.
Cong MaBreast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, No.116 Zhuo Daoquan South Road, Wuhan, 430079, Hubei, China.
Wenqin HuangBreast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, No.116 Zhuo Daoquan South Road, Wuhan, 430079, Hubei, China.
Senyang GuoBreast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, No.116 Zhuo Daoquan South Road, Wuhan, 430079, Hubei, China.
Lingzi WangBreast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, No.116 Zhuo Daoquan South Road, Wuhan, 430079, Hubei, China.
Hongmei ZhengBreast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, No.116 Zhuo Daoquan South Road, Wuhan, 430079, Hubei, China. 2022ZL0002@hust.edu.cn.
Xinhong WuBreast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, No.116 Zhuo Daoquan South Road, Wuhan, 430079, Hubei, China. 2019zl0002@hust.edu.cn.

Funding

Chutian Talent Project CTYC002National Key Specialized Construction Project HBCHBBC-A01Talent Project of Hubei Cancer Hospital 2025HBCHHHRC005Talent Project of Hubei Cancer Hospital 2025HBCHLHRC002Talent Project of Hubei Cancer Hospital 2025HBCHQHRC018Wu Jieping Fund Project 320.6750.2024-21-5 and 320.6750.2025-21-13
6 · The paper itself

Abstract

purposeBispecific antibody-drug conjugates (BsADCs) represent a promising strategy to overcome limitations of conventional ADCs in breast cancer, such as tumor heterogeneity and inefficient internalization. This review summarizes recent advances and the therapeutic potential of BsADCs.

methodsWe conducted a literature review, focusing on BsADC candidates selected for clinical relevance (e.g., ZW49, BL-B01D1), mechanistic innovation (e.g., biparatopic targeting, engaging fast-internalizing receptors), and potential in challenging subtypes like triple-negative breast cancer (TNBC).

resultsBsADCs enhance drug delivery through dual targeting. Biparatopic HER2-targeting agents (e.g., ZW49, JSKN003) induce receptor clustering and robust internalization. BsADCs co-engaging rapidly internalizing receptors (e.g., HER2×CD63) hijack efficient endocytic pathways, showing activity even in low HER2-expression models. Furthermore, BsADCs targeting compensatory pathways, such as EGFR×HER3 (BL-B01D1) and TROP2×HER3 (JSKN016), have demonstrated breakthrough efficacy in TNBC. Optimization of linker technology and drug-to-antibody ratio (DAR) has improved stability and the therapeutic window, enabling the progression of several BsADCs into Phase III trials.

conclusionBsADCs are a transformative therapeutic modality for breast cancer. Their ability to enhance tumor selectivity, overcome heterogeneity, and target resistant pathways positions them as key players in the future oncology landscape, with ongoing trials poised to define their clinical role.

Indexed as

Antibodies, BispecificBreast NeoplasmsImmunoconjugatesTriple Negative Breast NeoplasmsAnimalsErb-b2 Receptor Tyrosine KinasesFemaleHumansAntibodies, BispecificERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesBispecific antibody-drug conjugateBreast cancerDrug resistanceHER2Targeted therapyTROP2

Identifiers

PMID41579215
PMCPMC12831798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.